IL-1 in Focus: An Expert Question and Answer Session

These videos are promotional content funded by Sobi. This website is intended exclusively for healthcare professionals — meaning physicians, pharmacists, nurses, and other persons qualified to prescribe or supply medicinal products — within the European Union. It is not intended for members of the general public. If you are not a healthcare professional, please do not proceed. This website contains promotional material and educational resources relating to Sobi medicines.

Information is based on the Kineret Summary of Product Characteristics (SmPC) approved by the European Commission for use in the European Economic Area (EEA). SmPC/Prescribing information, product availability, and reimbursement conditions may vary by country. Before prescribing, always refer to locally approved SmPC and/or prescribing information. The SmPC approved for use in the EEA can be accessed here. Adverse Events Reporting Information, as well as further details, can be found at the bottom of this webpage.

Sobi has launched a four-part podcast series featuring leading experts in rheumatology, exploring the role of IL-1 in auto-inflammatory and autoimmune diseases. Across the series, discussions cover IL-1 in inflammation, treatment considerations and challenges in familial Mediterranean fever, the evolving landscape of Still’s disease, and approaches to targeting IL-1 in rheumatoid arthritis. In the short, question and answer-style clips below, hear from experts as they address important clinician questions.

Speakers:

Athimalaipet Ramanan

Paediatric Rheumatologist, Bristol Royal Hospital for Children; Professor of Paediatric Rheumatology, University of Bristol, UK

Helen Lachmann

Professor of Medicine, University College London; Consultant Physician, Royal Free Hospital, London, UK

Seza Özen

Paediatric Rheumatologist, Hacettepe University, Ankara, Türkiye; President-Elect, Paediatric Rheumatology European Society (PReS).

Serdal Uğurlu

Professor of Rheumatology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Türkiye.

Dennis McGonagle

Academic Rheumatologist, University of Leeds and Leeds Teaching Hospitals NHS Trust, UK.

Hugues Allard-Chamard

Adult Rheumatologist, Academic Centre, Université de Sherbrooke, Canada.

References:

1. Bahaahmadi A, et al. 2023;14:268.
2. Bashardoust B. J Nephropharmacol. 2015;4(1):5–8.
3.  Batu ED, et al. Rheumatology (Oxford). 2023:kead242.
4. Ben-Zvi I, et al. Arthritis Rheumatol. 2017;69(4):854–862.
5. Bhatt H, Cascella M. Familial Mediterranean Fever. StatPearls [Internet]. Last updated 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK560754/. Last accessed March 2026.
6. Broderick L, Hoffman HM. Nat Rev Rheumatol. 2022;18(8):448–463.
7. Choudhury D, et al., Cureus. 2021; doi:10.7759/cureus.17124.
8. Dinarello CA, et al. Nat Rev Drug Discov. 2012;11(8):633–652.
9. Dinarello CA, et al., Blood First Edition Paper. 2011.
10.  EMA. CHMP post-authorisation summary of positive opinion for Kineret. 2020.
11.  Eurofever Project [Internet]. Last updated 2023. Available at: https://www.printo.it/eurofever/score_criteria. Last accessed March 2026.
12.  Hausmann JS, et al. Orphanet J Rare Dis. 2018;13(1):156.
13.  Hentgen V, et al. Front Immunol. 2020;11:971.
14.  Hotta Y, Kawasaki T, Kotani T, et al. Intern Med. 2020;59(10):1267–1270.
15.  Kineret Scientific Discussion, EMEA 2004.
16.  Kineret® (anakinra) Summary of Product Characteristics. EMA. (2025). Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/kineret.
17.  Lopalco G, Cantarini L, Vitale A, et al. Mediators Inflamm. 2015;2015:194864.
18.  Marcuzzi A, et al. Int J Mol Sci. 2021;22(20):11241.
19.  McGonagle D and McDermott M. PLoS Med. 2006;3(8):297.
20.  McGonagle D, et al., Autoimmun Rev. 2018;17:675–81.
21.  Ozen S, et al. Ann Rheum Dis. 2016;75(4):644–651.
22.  Savic S, et al. RMD Open. 2017;3:e000550.
23.  Smolen JS, et al. Nat Rev Dis Primers. 2018;4:18001.
24.  Ugurlu S, et al. Rheumatology (Oxford). 2021;60(5):2327–2332.
25.  Wautier MP, et al. Int J Mol Sci. 2023;24:9647.

CAPS, Cryopyrin-Associated Periodic Syndromes; EULAR, European Alliance of Associations for Rheumatology; FMF, Familial Mediterranean Fever; IL-1, Interleukin-1; RA, Rheumatoid Arthritis.

To listen to the full podcasts where these clips are from, as well as exploring other interesting podcasts, click here https://thisiskineret.com/resources/.

The information on this website does not replace the full prescribing details for any product. Before making any treatment decisions, please consult the applicable Summary of Product Characteristics (“SmPC”) and all relevant prescribing information for your market. Please note that approved indications, dosing, availability, and reimbursement status for Sobi medicines may vary across EU member states. You should verify the regulatory status and approved conditions of use for any product in your own jurisdiction.

Patient safety is a priority for Sobi. We are committed to collect, analyse and react upon any new information about the benefits and risks of our products. If you have information about a side effect or suspected adverse reaction associated with any of our products, please let us know via [email protected].

Suspected adverse reactions should also be reported to your national health authority as applicable according to national legislation.

Copyright: Sobi and Kineret are trademarks of Swedish Orphan Biovitrum, AB (publ) © 2026 Swedish Orphan Biovitrum AB (publ) – All rights reserved www.sobi.com.

Job code & DOP: PP-31125 May 2026